Harvard Bioscience (HBIO) Stock Statistics & Valuation Metrics

Harvard Bioscience has a market cap or net worth of $21.49M. The enterprise value is $55.53M.

Harvard Bioscience has 44,531,197 shares outstanding. The number of shares has decreased by -2.65% in one year.

Harvard Bioscience’s return on equity (ROE) is -0.20 and return on invested capital (ROIC) is -6.02%.

The current PE Ratio of Harvard Bioscience is ―. Harvard Bioscience’s PEG ratio is ―.

In the last 12 months, Harvard Bioscience had revenue of 94.14M and earned -12.40M in profits. Earnings per share was -0.28.

In the last 12 months, operating cash flow was 6.62M and capital expenditures -1.56M, giving a free cash flow of 5.06M billion.

Harvard Bioscience pays an annual dividend of ―, resulting in a dividend yield of ―

Harvard Bioscience upcoming earnings date is Nov 6, 2025, After Close (Confirmed).

Harvard Bioscience as a current ratio of 0.82, with Debt / Equity ratio of 0.00%

In the past 12 months, Harvard Bioscience has paid 740.00K in taxes.

Harvard Bioscience EV to EBITDA ratio is -89.72, with an EV/FCF ratio of -109.84.

Harvard Bioscience has $7.44M in cash and marketable securities with $0.00 in debt, giving a net cash position of -$7.44M billion.

Gross margin is 56.89%, with operating margin of -6.60%, and net profit margin of -13.18%.

The average price target for Harvard Bioscience is $1.75, which is 11.43% higher than the current price. The consensus rating is Moderate Buy